Ikarian Capital LLC Sells 125,000 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Ikarian Capital LLC reduced its stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 40.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 180,857 shares of the company’s stock after selling 125,000 shares during the period. Ikarian Capital LLC’s holdings in Voyager Therapeutics were worth $1,684,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in VYGR. Ritholtz Wealth Management grew its stake in Voyager Therapeutics by 11.8% in the 4th quarter. Ritholtz Wealth Management now owns 19,759 shares of the company’s stock worth $167,000 after acquiring an additional 2,089 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of Voyager Therapeutics during the fourth quarter valued at approximately $43,000. Allspring Global Investments Holdings LLC boosted its stake in shares of Voyager Therapeutics by 27.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 97,276 shares of the company’s stock valued at $821,000 after purchasing an additional 20,916 shares in the last quarter. Cornercap Investment Counsel Inc. bought a new position in shares of Voyager Therapeutics during the fourth quarter valued at approximately $196,000. Finally, SummerHaven Investment Management LLC boosted its stake in shares of Voyager Therapeutics by 1.9% during the fourth quarter. SummerHaven Investment Management LLC now owns 74,146 shares of the company’s stock valued at $626,000 after purchasing an additional 1,367 shares in the last quarter. 48.03% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

VYGR has been the topic of a number of recent research reports. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research note on Wednesday. Wedbush dropped their price objective on shares of Voyager Therapeutics from $10.00 to $8.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 14th. StockNews.com downgraded shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, May 13th. Finally, Oppenheimer reiterated an “outperform” rating and set a $18.00 price objective on shares of Voyager Therapeutics in a research note on Wednesday, May 15th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $18.00.

Voyager Therapeutics Stock Performance

VYGR traded down $0.51 during trading on Thursday, hitting $8.68. The stock had a trading volume of 303,144 shares, compared to its average volume of 692,791. The company has a market capitalization of $472.11 million, a PE ratio of -173.57 and a beta of 0.96. Voyager Therapeutics, Inc. has a twelve month low of $6.06 and a twelve month high of $11.72. The stock has a 50 day simple moving average of $8.38 and a two-hundred day simple moving average of $8.38.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.24. The business had revenue of $19.52 million during the quarter, compared to analysts’ expectations of $10.33 million. Voyager Therapeutics had a negative net margin of 2.56% and a negative return on equity of 1.28%. On average, equities research analysts anticipate that Voyager Therapeutics, Inc. will post -1.39 EPS for the current year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.